Celestica is a strong company, with a remarkable and fortunate market position, but the valuation is now too high for strong ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended Senate Republican tax bill passes ‘SALT’ ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why investors should consider buying them hand over fist in July. Image source: ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in ...

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, United Health group and several other ...